Interesting article as they got John Martin to actually talk of...

Interesting article as they got John Martin to actually talk of the fact upfront money is on the table and that it was 5 down to 3 companies.


“But investors are waiting for something very specific: a pending licencing deal in Japan for Progenza, an off-the-shelf treatment for osteoarthritis pain.
On the company’s indications, they might not be waiting for much longer with a deal expected by early next year or even by Christmas.

Regeneus is already in rarefied company in Japan, having struck a 50:50 partnership with the country’s biggest drug manufacturer, AGC.

The licencing partner would fund the phase II trials and be responsible for distribution.

CEO John Martin says Regeneus was interested in five potential licencing partners, which was whittled to three, all of which are currently in due diligence.
In up-front monetary terms, he says the offers are similar. “It’s not a case of whose money is better but whether it will deliver a better outcome in terms of phase II and marketing.”

Full article:

http://www.biotechdaily.com.au/media/Dr Boreham/RGS Nov 16 2018.pdf